GSK: Australia accepts new filing for malaria drug

(CercleFinance.com) - GlaxoSmithKline said on Friday that Australia has accepted the filing for review of a new indication for its malaria drug Kozenis.


GSK and Medicines for Malaria Venture (MMV) said that the Australian Therapeutic Goods Administration (TGA) accepted the submission of an application to extend the indication of Kozenis to pediatric patients for prevention of relapse of the infectious disease.

The application includes data for a new tablet that can be disolved in water and which was developed to facilitate use in children, who are particularly affected by the disease.

Copyright (c) 2021 CercleFinance.com. All rights reserved.